Apontis Pharma AG

    Jurisdiction
    Germany
    LEI
    894500ETO1J6MR8PDF91
    ISIN
    DE000A3CMGM5 (APPH.DE)
    Sectors
    1. Healthcare
    2. Drug Manufacturers - Specialty & Generic

    Scores

    InsiderPie Expert Score
    56 / 100
    Even with peer group:
    56 / 100
    Fair value (Benjamin Graham formula)
    €27.91 159.6% undervalued
    Fundamental strength relative to industry (Mohanram G-Value)
    0 / 7

    Profile

    Apontis Pharma AG markets and sells medical drugs for indication fields of internal medicine in Germany. Read full profile

    Fundamentals

    Net revenue
    €85.43M
    Gross margin
    9.5%
    EBIT
    -€14.84M
    EBIT margin
    -17.4%
    Net income
    -€10.55M
    Net margin
    -12.3%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €54.90M -35.7% €2.70M -125.6%
    €67.90M +23.7% €6.20M +129.6%
    N/A N/A

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    No insider transactions in the last 90 days. View older insider transactions

    Earnings Calls

    Add to watchlist

    Notifications